AIRLINK 80.60 Increased By ▲ 1.19 (1.5%)
BOP 5.28 Decreased By ▼ -0.05 (-0.94%)
CNERGY 4.37 Decreased By ▼ -0.01 (-0.23%)
DFML 35.10 Increased By ▲ 1.91 (5.75%)
DGKC 76.90 Increased By ▲ 0.03 (0.04%)
FCCL 20.60 Increased By ▲ 0.07 (0.34%)
FFBL 31.75 Increased By ▲ 0.35 (1.11%)
FFL 9.75 Decreased By ▼ -0.10 (-1.02%)
GGL 10.20 Decreased By ▼ -0.05 (-0.49%)
HBL 117.50 Decreased By ▼ -0.43 (-0.36%)
HUBC 134.51 Increased By ▲ 0.41 (0.31%)
HUMNL 7.00 No Change ▼ 0.00 (0%)
KEL 4.52 Decreased By ▼ -0.15 (-3.21%)
KOSM 4.69 Decreased By ▼ -0.05 (-1.05%)
MLCF 37.40 Decreased By ▼ -0.04 (-0.11%)
OGDC 136.60 Decreased By ▼ -0.10 (-0.07%)
PAEL 23.20 Increased By ▲ 0.05 (0.22%)
PIAA 27.09 Increased By ▲ 0.54 (2.03%)
PIBTL 6.90 Decreased By ▼ -0.10 (-1.43%)
PPL 113.60 Decreased By ▼ -0.15 (-0.13%)
PRL 27.38 Decreased By ▼ -0.14 (-0.51%)
PTC 14.85 Increased By ▲ 0.10 (0.68%)
SEARL 57.25 Increased By ▲ 0.05 (0.09%)
SNGP 67.00 Decreased By ▼ -0.50 (-0.74%)
SSGC 11.01 Decreased By ▼ -0.08 (-0.72%)
TELE 9.26 Increased By ▲ 0.03 (0.33%)
TPLP 11.61 Increased By ▲ 0.05 (0.43%)
TRG 72.20 Increased By ▲ 0.10 (0.14%)
UNITY 25.57 Increased By ▲ 0.75 (3.02%)
WTL 1.39 Decreased By ▼ -0.01 (-0.71%)
BR100 7,552 Increased By 26.6 (0.35%)
BR30 24,664 Increased By 14.6 (0.06%)
KSE100 72,103 Increased By 131.3 (0.18%)
KSE30 23,808 Increased By 59 (0.25%)

THE HAGUE: The EU’s medicines regulator said Tuesday it was “firmly convinced” the benefits of AstraZeneca’s jab outweigh potential risks, insisting there was no evidence linking the vaccine to blood clots after a host of nations suspended the shot over health fears.

The suspensions have led to intense debate over whether it was prudent to put AstraZeneca inoculations on hold just as vaccination campaigns begin to gather pace in many countries.

Experts at both the World Health Organization and the European Medicines Agency met Tuesday to discuss the vaccine, with the European organisation expected to publish conclusions Thursday.

While millions of doses of the vaccine developed with Oxford University have been administered, small numbers of people have developed blood clots, prompting countries including the European Union’s three largest nations — Germany, France and Italy — to suspend injections.

But the EMA insisted Tuesday that countries should continue using the vaccine. “We are still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19 with its associated risk of hospitalisation and death outweigh the risk of these side effects,” EMA chief Emer Cooke said. “At present there is no indication that vaccination has caused these conditions,” she added, echoing the WHO and drugmaker AstraZeneca itself.

Cooke noted however that the regulator was “looking at adverse events associated with all vaccines”.

Meanwhile deaths across the continent have topped 900,000, making it the worst-hit global region in absolute terms, according to an AFP tally from official figures.

In Britain, which has administered more than 11 million AstraZeneca doses and where experts see no evidence of more frequent blood clots among the inoculated, Prime Minister Boris Johnson wrote in the Times newspaper that the shot “is safe and works extremely well”.

“There were a few very unusual and troubling cases which justify this pause and the analysis,” Fischer told France Inter radio.

Three big European powers — Germany, Italy and France — all suspended AstraZeneca this week, joining several other countries that have halted or delayed the rollout, including Indonesia, Venezuela, Sweden and the Netherlands. But in Canada, Prime Minister Justin Trudeau urged citizens to get the AstraZeneca shot after reports of hesitancy based on the suspensions.

And Thai Prime Minister Prayut Chan-O-Cha was himself injected Tuesday as his country lifted its own AstraZeneca suspension.

The pandemic spurred unprecedented efforts to develop vaccines, with a number of successful options now available.

Comments

Comments are closed.